Imidazolone derivatives, method for the preparation thereof and biological applications
View Patent ↗Imidazolone derivatives, as medicaments, of formula wherein: R 1 ═H, C 1 to C 5 alkyl, aryl or a 5- or 6-membered heterocyclic group; Ar 1 =optionally substituted aryl or an aromatic heterocycle; R═R 2 —S—, R 3 —HN—, R 4 COHN or Ar 2 , with R 2 =a C 1 -C 5 alkyl, vinyl or vinyl(C 1 -C 5 )alkyl, nitrile or nitrile(C 1 -C 5 )alkyl, aryl or benzyl radical, which are optionally substituted; R 3 =the meanings given above and H; Ar 2 =substituted or unsubstituted aryl.
1. An imidazolone derivative, characterized in that said derivative corresponds to formula (I)
in which:
R 1 represents a C 1 -C 3 alkyl radical or a hydrogen atom, and/or an aryl radical
Ar 1 is chosen from
R represents
an R 2 —S— group, R 2 then being chosen from radicals represented by T 1 -(CH 2 ) n , with n=0, 1, 2 or 3 and T 1 representing one of the following radicals: methyl, vinyl, alkyl, alkynyl, nitrile, cycloalkyl, which may be C 3 or C 4 , Z—O, Z—CO, with Z═C 1 -C 3 alkyl, or hal, hal representing F, Cl, Br or I or a CCl 3 group,
or
an R 3 —NH— group, R 3 then being chosen from radicals represented by T 2 -(CH 2 ) n , with n=0, 1 or 2, and T 2 representing one of the following radicals: methyl, vinyl, ZO, ZO—CONH—, —CH—(OZ) 2 , ZCO, with Z═H or linear or branched C 1 -C 4 alkyl, NH 2 , C 3 cycloalkyl, aryl or substituted aryl, or R 2 ═H,
or
an R 4 —CONH— group, R 4 then being a branched C 3 -C 5 alkyl radical,
or
Ar 2 or Ar 2 —S, Ar 2 being chosen from a phenyl, substituted phenyl or benzodioxolyl radical,
and an IC 50 of less than 5 μM.
2. The derivative as claimed in claim 1 , characterized in that it has an IC 50 of less than 1 μM and corresponds to formula (I) in which:
R 1 represents H or CH 3
Ar 1 represents the radical
R 3 represents an R 2 —S— group, R 2 then being chosen from radicals represented by T 1 -(CH 2 ) n , with T 1 =a methyl, alkynyl, nitrile, hal, CH 3 O, cyclopropyl or cyclobutyl radical, n=0, 1, 2 or 3, “hal” representing a halogen atom or a CCl 3 group,
or
an R 3 —HN— group, R 3 then being chosen from radicals represented by T 2 -(CH 2 ) n , with T 2 =C 3 alkyl, OH, cyclopropyl, phenyl, phenyl substituted with OH, OCH 3 , COOH and OH, CH 2 OH, C(CH 3 , OH), CH 2 —CH 2 OH, CH 2 —COOH or benzodioxolyl, or R 2 ═H, n=0, 1 or 2,
or
an Ar 2 group chosen from a para-hydroxyphenyl or benzodioxolyl group.
3. The derivative as claimed in claim 1 , characterized in that it is chosen from the derivatives of formula (I) in which
R═R 2 S
R 2 ═CH 2 C≡CH; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 C≡N; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 CH 2 Cl; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 3 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 CH 3 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 CH 2 CH 3 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH(CH 3 ) 2 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 C≡N; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 (CH 2 ) 2 CH 3 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 CH 2 OCH 3 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 T 1 with T 1 =cyclopropyl; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 2 ═CH 2 T 1 with T 1 =cyclobutyl; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R═R 3 NH
R 3 ═CH 2 CH 3 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═CH 2 CH 2 OH; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═CH 2 T 1 with T 1 =cyclopropyl; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═CH 2 CH 3 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =o-HO—C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═C 6 H 5 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-HO—C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-HO-m-HO 2 C—C 6 H 3 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-m-OCH 2 O—C 6 H 3 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-CH 3 —C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═HOCH 2 CHOHCH 2 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-m-OCH 2 CH 2 O—C 6 H 3 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-CH 3 O—C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =m-HOCH 2 —C 6 H 4 , R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =m-HOCH(CH 3 )—C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-HOCH 2 CH 2 —C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-HO 2 CCH 2 O—C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═CH 2 CH 2 CH 3 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═CH 2 T 1 with T 1 =cyclopropyl; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═C 6 H 5 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 3 =p-HO—C 6 H 4 ; R 1 ═H; Ar 1 =1,3-benzodioxol-5-yl
R 3 ═H; R 1 ═H; Ar 1 =p-HO-m-MeO—C 6 H 3
R═Ar 2
Ar 2 =p-HO—C 6 H 4 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl
Ar 2 =p-m-OCH 2 O—C 6 H 3 ; R 1 =Me; Ar 1 =1,3-benzodioxol-5-yl.
4. A pharmaceutical composition, characterized in that it contains a therapeutically effective amount of at least one derivative as claimed in claim 1 .